-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Benzinga·09/10/2026 13:08:39
Listen to the news
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.